Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A+CHP in Frontline PTCL with Low CD30 Expression
2023-509155-14-00Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Dec 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in peripheral T-cell lymphoma (PTCL), sponsored by Seagen Inc. Primary endpoint: Overall response rate per BICR (Revised Response Criteria for Malignant Lymphoma). Started Dec 2023; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on 2023-509155-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509155-14-00.